Dizal Pharmaceutical’s Sunvozertinib Earns Breakthrough Designation for NSCLC from China’s NMPA
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a biopharmaceutical company based in China, has announced that...
Cancer
Pfizer’s Talzenna Combo Shows Improved Survival in mCRPC Patients, According to TALAPRO-2 Study
Pfizer Inc. (NYSE: PFE) has announced positive topline results regarding overall survival (OS) in the...
CSPC Pharma Initiates Phase III Trial for JMT101 in First-Line EGFR-Positive NSCLC Treatment
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has initiated...
KangaBio’s KGX101 Receives NMPA Approval for Clinical Trial in China
KangaBio, a biopharmaceutical company based in Shanghai, has announced that its investigational new drug (IND)...
Immupeutics Medicine Secures NMPA Approval for Personalized Liver Cancer Immunotherapy IPM001
Immupeutics Medicine, a pioneer in tumor immunotherapy based in Beijing, has announced that it has...
Coherent Biopharma’s CBP-1008 Earns FDA Fast Track for Platinum-Resistant Ovarian Cancer
Coherent Biopharma Ltd, a specialist in bispecific-ligand drug conjugates (Bi-XDCs) with operations in Suzhou, China,...
Doma Biopharmaceutical Receives Green Light for Clinical Trial of Novel ADC DM001 Targeting Solid Tumors
Doma Biopharmaceutical (Suzhou) Co., Ltd, a biotech firm with a presence in China and the...
Harbour BioMed’s Innovative Antibody Porustobart Shows Promise in Early Clinical Trials for Melanoma
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...
Sunvozertinib’s Companion Diagnostic Gets NMPA Nod, Fortifying Targeted Therapy Arsenal for NSCLC in China
Dizal Pharmaceutical Co., Ltd (SHA: 688192) and Burning Rock Ltd (NASDAQ: BNR, FRA: 6BU0) have...
Nona Biosciences Partners with OverT Bio to Develop Next-Generation Cell Therapies for Solid Tumors
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...
Merck’s Keytruda Meets Primary Endpoint in Phase III Study for Head and Neck Cancer
US pharmaceutical giant Merck & Co., Inc. (MRK, NYSE: MRK) has announced that the Phase...
CSPC Pharmaceutical’s ADC CPO301 Earns Second Fast-Track Designation in the US for NSCLC Treatment
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its best-in-class antibody drug conjugate...
Ascentage Pharma Receives Approval for Two Phase III Trials of APG-2449 in NSCLC
China-based biopharmaceutical company Ascentage Pharma (HKG: 6855) has announced that it has received approval from...
Innovent Biologics and ASK Pharma Forge Strategic Partnership for Limertinib in Lung Cancer Treatment
China-based Innovent Biologics Inc. (HKG: 1801) and Jiangsu Aosaikang Pharmaceutical Co., Ltd (ASK Pharma, SHE:...
MediLink Therapeutics Partners with Amgen for Clinical Trial in Small Cell Lung Cancer
Suzhou-based biotech MediLink Therapeutics (Suzhou) Co., Ltd has announced a partnership with US pharmaceutical giant...
BeiGene Prices TEVIMBRA 10% Below Competitors Following FDA Approval for Esophageal Cancer Treatment
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the commercial availability of TEVIMBRA (Tislelizumab)...
BMS Expands Opdivo Indication with FDA Approval for NSCLC Combo Therapy
The U.S. Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS,...
Akeso Biopharma’s PD-1/VEGF Bispecific Antibody Study Completes Enrollment
On October 4, 2024, Summit Therapeutics (referred to as “Summit”), a partner of Akeso Biopharma...
FRα ADC Rina-S by Genmab Enters Late-Stage Clinical Trial Following ProfoundBio Acquisition
Genmab A/S (NASDAQ: GMAB) has initiated a Phase III clinical trial for its FRα ADC...
Dizal Pharmaceutical’s Surufatinib Earns CDE Consideration for Breakthrough Therapy in EGFR exon20ins NSCLC
Dizal Pharmaceutical, a biopharmaceutical company based in China, has announced that the Center for Drug...